Healthcare Losers: Cytokinetics (NASDAQ:CYTK), Achillion Pharmaceuticals (NASDAQ:ACHN), Pharmacyclics (NASDAQ:PCYC), Organovo Holdings Inc (NYSEMKT:ONVO)

Cytokinetics, Inc. (NASDAQ:CYTK) announced disappointing top-line results from its BENEFIT-ALS midstage study involving tirasemtiv. Tirasemtiv did not meet its primary efficacy endpoint of delivering a mean change from baseline in the ALS functional rating scale. Cytokinetics, Inc. (NASDAQ:CYTK) stock performance was -64.67% in last session and finished the day at $4.59. Traded volume was 17.26million…

Read More

Biotech Bearish Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Galena Biopharma (NASDAQ:GALE), Insmed Incorporated (NASDAQ:INSM), CytRx Corporation (NASDAQ:CYTR)

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) was upgraded by investment analysts at Maxim Group from a “hold” rating to a “buy” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm currently has a $6.00 price target on the stock. Maxim Group’s target price would suggest a potential upside of 62.16% from the stock’s…

Read More

Biotech Losers: Novavax (NASDAQ:NVAX), Achillion Pharmaceuticals (NASDAQ:ACHN), The Clorox (NYSE:CLX), Halozyme Therapeutics (NASDAQ:HALO)

Novavax, Inc. (NASDAQ:NVAX) is a vaccine company that is likely to have multiple milestones this year. It has U.S. government funding for seasonal and pandemic flu, and is developing its own products for respiratory syncytial virus (RSV). Novavax, Inc. (NASDAQ:NVAX) stock performance was -5.02% in last session and finished the day at $6.05. Traded volume…

Read More